Drugs / ABI-1968
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03697226 | Dec 2018 → May 2020 | cervical cancer, cervical intraepithelial neoplasia grade 2/3, cervical squamous intraepithelial neoplasia, human papilloma virus infection | Antiva Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03677960 | Dec 2018 → Jun 2019 | HIV infectious disease, anal carcinoma, human papilloma virus infection, squamous cell intraepithelial neoplasia | Antiva Biosciences | Terminated | No outcome recorded |
| Phase 1 | NCT03239223 | Jan → Oct 2018 | cervical cancer, cervical intraepithelial neoplasia grade 2/3, cervical squamous intraepithelial neoplasia, human papilloma virus infection | Antiva Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03202992 | Aug 2017 → Feb 2019 | HIV infectious disease, anal carcinoma, human papilloma virus infection, squamous cell intraepithelial neoplasia | Antiva Biosciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-1968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03677960 ↗ |
| Route | Topical | “Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion” NCT03202992 ↗ |